Business
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager for the treatment of autoimmune diseases, as an oral presentation at the 2026 Immune Resetting:
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IBI3055, a proprietary anti-CD19/BCMA/CD3 tri-specific T cell engager for the treatment of autoimmune diseases, as an oral presentation at the 2026 Immune Resetting: B-Cell Mediated & Beyond Summit in Boston, Massachusetts (USA). IBI3055 is a novel tri-specific antibody targeting CD19, B-cell maturation antigen (BCMA), and CD3. It is built on an innovative "1+1+1" T-cell engager format and incorporates steric hindrance-based CD3 masking to reduce non-specific T-cell activation, aiming to achieve an optimal balance between potent immune cell depletion and favorable safety profile. IBI3055 is intended for the treatment of various B cell- or plasma cell-mediated autoimmune diseases.","length":1110,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"IBI3055 employs a unique "1+1+1" design with CD3 masking, enabling target-dependent T cell activation and potentially improving safety and pharmacokinetic properties.","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"IBI3055 demonstrates effective cytotoxicity against either CD19- or BCMA-positive cells across varying expression levels, with potency comparable to corresponding mono-targeting T cell engagers.","length":194,"tagName":"p"}]},{"val":[{"type":"text","content":"In human CD19/BCMA/CD3 transgenic mouse models, IBI3055 induces deep depletion of B cells and plasma cells in peripheral blood, spleen, lymph nodes, and bone marrow, along with significant reductions in circulating immunoglobulin levels, showing greater activity than mono-targeting CD19 or BCMA T-cell engagers.","length":312,"tagName":"p"}]},{"val":[{"type":"text","content":"In non-human primates, IBI3055 also achieves profound depletion of B cells and plasma cells across multiple compartments and significantly reduces circulating immunoglobulins, while demonstrating favorable safety and tolerability.","length":230,"tagName":"p"}]}],"tagName":"ul","bulletedList...